Towa Pharmaceutical Co., Ltd. (FRA:6QC)
Germany · Delayed Price · Currency is EUR 17.50
+0.40 (2.34%)
At close: Nov 28, 2025
Towa Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 266,666 | 259,594 | 227,934 | 208,859 | 165,615 | 154,900 | Upgrade | |
Revenue Growth (YoY) | 9.31% | 13.89% | 9.13% | 26.11% | 6.92% | 40.33% | Upgrade |
Cost of Revenue | 169,645 | 164,865 | 146,551 | 136,145 | 95,429 | 89,448 | Upgrade |
Gross Profit | 97,021 | 94,729 | 81,383 | 72,714 | 70,186 | 65,452 | Upgrade |
Selling, General & Admin | 57,316 | 54,954 | 50,405 | 51,825 | 39,381 | 34,842 | Upgrade |
Research & Development | 16,212 | 16,212 | 13,242 | 15,265 | 11,488 | 10,642 | Upgrade |
Operating Expenses | 73,848 | 71,486 | 63,735 | 67,199 | 51,648 | 45,523 | Upgrade |
Operating Income | 23,173 | 23,243 | 17,648 | 5,515 | 18,538 | 19,929 | Upgrade |
Interest Expense | -2,000 | -1,627 | -947 | -635 | -230 | -190 | Upgrade |
Interest & Investment Income | 269 | 232 | 106 | 25 | 14 | 29 | Upgrade |
Currency Exchange Gain (Loss) | 1,208 | 1,992 | 1,593 | 1,181 | 795 | 770 | Upgrade |
Other Non Operating Income (Expenses) | 1,100 | 1,051 | 527 | 905 | 725 | 527 | Upgrade |
EBT Excluding Unusual Items | 23,750 | 24,891 | 18,927 | 6,991 | 19,842 | 21,065 | Upgrade |
Gain (Loss) on Sale of Investments | -11 | -38 | -222 | -20 | -563 | -45 | Upgrade |
Gain (Loss) on Sale of Assets | 211 | 230 | 225 | -46 | 96 | 97 | Upgrade |
Asset Writedown | 4,035 | 1,247 | 5,550 | -2,282 | 2,896 | -2,388 | Upgrade |
Other Unusual Items | - | -1 | -21 | -38 | -26 | -1 | Upgrade |
Pretax Income | 27,985 | 26,329 | 24,459 | 4,605 | 22,245 | 18,728 | Upgrade |
Income Tax Expense | 7,340 | 7,343 | 8,286 | 2,404 | 6,331 | 4,770 | Upgrade |
Net Income | 20,645 | 18,986 | 16,173 | 2,201 | 15,914 | 13,958 | Upgrade |
Net Income to Common | 20,645 | 18,986 | 16,173 | 2,201 | 15,914 | 13,958 | Upgrade |
Net Income Growth | 30.87% | 17.39% | 634.80% | -86.17% | 14.01% | -3.76% | Upgrade |
Shares Outstanding (Basic) | 49 | 49 | 49 | 49 | 49 | 49 | Upgrade |
Shares Outstanding (Diluted) | 49 | 49 | 49 | 49 | 50 | 51 | Upgrade |
Shares Change (YoY) | 0.01% | 0.01% | -0.00% | -2.19% | -1.86% | -3.57% | Upgrade |
EPS (Basic) | 419.38 | 385.70 | 328.58 | 44.72 | 323.35 | 283.62 | Upgrade |
EPS (Diluted) | 419.38 | 385.70 | 328.58 | 44.72 | 316.19 | 271.93 | Upgrade |
EPS Growth | 30.86% | 17.38% | 634.82% | -85.86% | 16.28% | -0.25% | Upgrade |
Free Cash Flow | -1,132 | -5,335 | -29,639 | -26,187 | 10,989 | 2,871 | Upgrade |
Free Cash Flow Per Share | -23.00 | -108.38 | -602.17 | -532.02 | 218.36 | 55.99 | Upgrade |
Dividend Per Share | 40.000 | 70.000 | 60.000 | 60.000 | 57.000 | 44.000 | Upgrade |
Dividend Growth | -33.33% | 16.67% | - | 5.26% | 29.54% | - | Upgrade |
Gross Margin | 36.38% | 36.49% | 35.70% | 34.82% | 42.38% | 42.25% | Upgrade |
Operating Margin | 8.69% | 8.95% | 7.74% | 2.64% | 11.19% | 12.87% | Upgrade |
Profit Margin | 7.74% | 7.31% | 7.09% | 1.05% | 9.61% | 9.01% | Upgrade |
Free Cash Flow Margin | -0.43% | -2.05% | -13.00% | -12.54% | 6.64% | 1.85% | Upgrade |
EBITDA | 44,578 | 43,342 | 35,536 | 24,924 | 29,492 | 30,354 | Upgrade |
EBITDA Margin | 16.72% | 16.70% | 15.59% | 11.93% | 17.81% | 19.60% | Upgrade |
D&A For EBITDA | 21,405 | 20,099 | 17,888 | 19,409 | 10,954 | 10,425 | Upgrade |
EBIT | 23,173 | 23,243 | 17,648 | 5,515 | 18,538 | 19,929 | Upgrade |
EBIT Margin | 8.69% | 8.95% | 7.74% | 2.64% | 11.19% | 12.87% | Upgrade |
Effective Tax Rate | 26.23% | 27.89% | 33.88% | 52.20% | 28.46% | 25.47% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.